Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 5Terminated 4Suspended 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 1Other 1Lymphoid 1

Conditions

Osteosarcoma 2Mucositis 1Lymphoma, Large B-Cell, Diffuse 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Interventional × glucarpidase × Clear all
NCT05022797 2024-05-13

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

Fundacion CRIS de Investigación para Vencer el Cáncer

Phase 2 Terminated
3 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Drug-Related Side Effects and Adverse Reactions

NCT02022358 2015-06-04

Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

University College, London

Phase 2 Terminated
34 enrolled
OtherSarcoma

Osteosarcoma, Mucositis

NCT00634322 2014-09-15

High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma

BTG International Inc.

Phase 2 Terminated
7 enrolled 7 charts
Sarcoma

Osteosarcoma

NCT00424645 2012-12-06

Voraxaze for Delayed Methotrexate Clearance

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 2 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡